ALX Oncology Holdings Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.22 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 168.70M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Details
| Name | ALX Oncology Holdings Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 48 |
| Founded | 2015 |
| Ipo Date | 2020-07-17 |
| Ceo | Jason Lettmann |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 19.00 |
| Isin | US00166B1052 |
| Cusip | 00166B105 |
| Cik | 1810182 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Jason W. Lettmann | Chief Executive Officer and Director |
| Harish Shantharam C.F.A. | Chief Financial Officer |
| Shelly Wong C.P.A. | Senior Vice President of Finance and Chief Accounting Officer |
| Dr. Barbara J. Klencke M.D. | Chief Medical Officer |
| Jeff E. Knight M.P.H. | Chief Development and Operating Officer |
| Michael Listgarten | General Counsel |
| Dr. Athanasios Tsiatis M.D. | Senior Vice President of Clinical Development |
| Dr. Lin Yeong-Liang M.D., M.S. | Senior Vice President of Drug Safety and Pharmacovigilance |
| Lisa Sauer | Senior Vice President of Regulatory Affairs and Quality Assurance |
| Sue Naim | Senior Vice President of Clinical Operations |
Contact
| Address | 323 Allerton Avenue, South San Francisco, California 94080, United States |
| Phone | 650 466 7125 |
| Website | https://www.alxoncology.com |